Thursday, 5 November 2026European Markets
ExploreSearch
ViaNews EU
Via News Knowledge File

Anthropic

organization80% conf.·synced Nov 5, 2026

AI company developing Claude AI assistant

59
sourced metrics
1926
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Market Cap
380000000000USD
⚠ sources conflictsource
Projected Ipo Valuation
2000USD
source
Potential Ipo Valuation
60USD
source
New Customer Preference
73.3percent
source
Exposed Assets Count
3000assets
source
Ipo Prospectus Length
335pages
Oct 26, 2026source
Prospectus Length
335pages
Oct 26, 2026source
Ipo Valuation Target
2000USD
Oct 22, 2026source
Annualized Revenue Run Rate
67USD
Sep 30, 2026source
Infrastructure Commitments
518USD
Sep 29, 2026source
Acquisition Count
5acquisitions
Sep 29, 2026source
Noncancelable Commitments Share
80percent
Sep 29, 2026source
Cumulative Funding Raised
125USD
Sep 2, 2026source
Compute Capacity Secured
5gigawatts
Aug 31, 2026source
Acquisition Count This Year
5companies
Aug 24, 2026source
Purchase Consideration Rate
29percent
Jul 16, 2026source
Market Share
40percent
Jul 15, 2026source
Employee Count Growth Yoy
183percent
Jul 2, 2026source

Stated objectives

Complete $50 billion US data center buildout

source
target: 50 billion USD stated

Prove that superior orchestration of existing models can yield exponential productivity gains as alternative to trillion-dollar infrastructure build-outs

source
stated

Halt training or delete model weights if safety and security standards cannot be met

source
stated

Target users running Claude Code continuously in the background 24/7 with new rate limits

source
target: less than 5 percent of users affected stated

Race to develop expert-level and superhuman AI systems

source
stated

Expand Cowork beyond macOS to Windows and add cross-device sync, growing access beyond Claude Max subscribers

source
stated

Make working with Claude feel less like operating a tool and more like delegating to a colleague, targeting mainstream non-technical users

source
stated

Continue developing agent safety mechanisms including defenses against prompt injection attacks as an active area of development

source
stated

Anthropic reportedly targeting its own IPO

source
stated

Diversify compute supply beyond Nvidia by expanding use of Amazon Trainium and Google TPUs to reduce concentration risk and improve hardware availability

source
stated

Relationship graph · 1926 connections

Competes with
562
Developed by
486
Customer of
160
Invested in
141
Supplies to
125
Employs
119
regulates
63
Covered by
34
Invested in
Nvidia

Via News coverage

Micron's Spending Tripled in Two Years as the AI Buildout Reached Memory Chips, While Weaker Corners of the Market Were Left Behind
October 1, 2026
AI Lab Leaders Disclaim Authority Over Societal AI Governance Amid EU Regulatory Push
March 17, 2026
Anthropic Launches Court Challenge Against Pentagon AI Designation as EU Companies Navigate Dual Regulatory Framework
March 15, 2026
Pentagon Labels Anthropic Supply Chain Risk as Defense AI Contracts Face Regulatory Overhaul
March 14, 2026
Pentagon signs AI deals with OpenAI and Google as Anthropic reverses course on defense work
March 13, 2026
EU Accelerates AI Safety Rules After Pentagon Claude Ban and Gemini Lawsuit
March 13, 2026
Anthropic sues Pentagon over supply chain ban as AI labs face military-commercial split
March 12, 2026
EU Caught Between Open AI Access and US-China Tech Race as Governance Models Diverge
March 11, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com